From these data, short‐term hematologic toxicities during breast cancer chemotherapy appear similar which should be reassuring for clinicians administering, and patients with a BRCA1 or BRCA2 mutation receiving, chemotherapy. This evidence concerns the gene BRCA1 and breast carcinoma.